Omega-3 Supplementation Positively Affects Cardiovascular Disease Patients And Could Save Costs
October 27, 2023
Depressive Symptoms Tied to Higher Mortality Risk in U.S. Adults
October 27, 2023

Bayer Must Pay $1.25 Million In Roundup Cancer Trial, Jury Finds


Bayer must pay $1.25 million to a man who sued the company alleging he developed cancer from exposure to its Roundup weedkiller, a jury in St. Louis, Missouri has found.


Like many of the plaintiffs suing Bayer over Roundup, the man at the center of this case says he developed a type of cancer known as non-Hodgkin lymphoma as a result of exposure to the weedkiller. Roundup-related lawsuits have plagued Bayer since it acquired the brand as part of its disastrous $63 billion purchase of agrochemicals firm Monsanto in 2018. Bayer settled most of the claims in 2020 for around $10.9 billion, but still faces almost 40,000 additional cases.

Meanwhile, with American lawyers still actively seeking new plaintiffs, the Roundup class action is ongoing. In this situation, with Bayer’s stock price having nosedived by more than 50 percent since 2015, many of the firm’s investors are pushing for Monsanto to be cut off and sold. The World Health Organization’s International Agency for Research on Cancer (IARC) acknowledged in 2015 that glyphosate was “probably carcinogenic to humans,” and studies have since provided “compelling evidence” that the chemical increases the risk of developing non-Hodgkin lymphoma.

To read more about rumors that the corporate marriage between Bayer and Monsanto may be heading for divorce, see this article on our website.